The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis

Research output: Contribution to journalArticle

Authors

Colleges, School and Institutes

External organisations

  • Developmental and Molecular Immunology, Department of Biomedicine, University of Basel

Abstract

The cytokine Fms-like tyrosine kinase 3 ligand (FL) is an important regulator of hematopoiesis. Its receptor, Flt3, is expressed on myeloid, lymphoid and dendritic cell progenitors and is considered an important growth and differentiation factor for several hematopoietic lineages. Activating mutations of Flt3 are frequently found in acute myeloid leukemia (AML) patients and associated with a poor clinical prognosis. In the present review we provide an overview of our current knowledge on the role of FL in the generation of blood cell lineages. We examine recent studies on Flt3 expression by hematopoietic stem cells and its potential instructive action at early stages of hematopoiesis. In addition, we review current findings on the role of mutated FLT3 in leukemia and the development of FLT3 inhibitors for therapeutic use to treat AML. The importance of mouse models in elucidating the role of Flt3-ligand in normal and malignant hematopoiesis is discussed

Details

Original languageEnglish
Pages (from-to)1115
JournalInternational Journal of Molecular Sciences
Volume18
Issue number6
Publication statusPublished - 24 May 2017

Keywords

  • Flt3 , hematopoiesis , acute myeloid leukemia (AML) , cytokines , Flt3 with internal tandem duplications (FLT3-ITD)